<DOC>
	<DOCNO>NCT00655044</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study evaluate incidence serious adverse drug reaction use Levemir® normal clinical practice condition .</brief_summary>
	<brief_title>Evaluation Levemir® Treatment Type 1 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 1 diabetes Type 2 diabetes Candidates use basal insulin part diabetes regimen Unwilling adhere therapy follow Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>